Celldex Therapeutics (CLDX) is a clinical-stage biotechnology company that focuses on developing targeted therapies for rare and difficult-to-treat diseases, specializing in immuno-oncology and autoimmune disorders. Positive data from its pipeline candidates - particularly CDX-0159, a drug under development for the treatment of chronic urticaria (hives) and other mast cell-driven diseases - has piqued analysts' interest.
CLDX stock has fallen 27.7% year-to-date, while the S&P 500 Index ($SPX) has risen 22.7%. Nonetheless, Wall Street expects the stock to skyrocket nearly 135% over the next 12 months, based on analysts' average price target.
